SCHEMBL13524740

SCHEMBL13524740

COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)c2cc1C

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 20/20 0.88
CSF1R P07333 3/20 0.77
KIT P10721 3/20 0.77
FLT3 P36888 3/20 0.77
PLK4 O00444 1/20 0.71
GAK O14976 1/20 0.71
EPHB6 O15197 1/20 0.71
STK10 O94804 1/20 0.71
EGFR P00533 1/20 0.71
NTRK1 P04629 1/20 0.71
LCK P06239 1/20 0.71
FGFR1 P11362 1/20 0.71
SRC P12931 1/20 0.71
PDGFRA P16234 1/20 0.71
FLT1 P17948 1/20 0.71
FGFR2 P21802 1/20 0.71
FGFR4 P22455 1/20 0.71
FGFR3 P22607 1/20 0.71
AXL P30530 1/20 0.71
FLT4 P35916 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13524742 0.96 PDGFRB (0.88) PDGFRBCSF1RKITFLT3PLK4
SCHEMBL2923104 0.94 PDGFRB (1.00) PDGFRBCSF1RKITFLT3PLK4
SCHEMBL14009840 0.89 PDGFRB (0.90) PDGFRBCSF1RKITFLT3PLK4
SCHEMBL13330487 0.89 PDGFRB (0.90) PDGFRBCSF1RKITFLT3PLK4
SCHEMBL13773461 0.88 PDGFRB (0.85) PDGFRBCSF1RKITFLT3PLK4
SCHEMBL3891757 0.87 PDGFRB (1.00) PDGFRBCSF1RKITFLT3PLK4
SCHEMBL13330496 0.86 PDGFRB (0.84) PDGFRBCSF1RKITFLT3PLK4
SCHEMBL13330491 0.86 PDGFRB (0.84) PDGFRBCSF1RKITFLT3PLK4
SCHEMBL2921324 0.85 PDGFRB (0.84) PDGFRBCSF1RKITFLT3FGFR1
SCHEMBL2922051 0.85 PDGFRB (1.00) PDGFRBKITFLT3FGFR1PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100022467-A1 ANTI-CANCER PHOSPHONATE ANALOGS BOOJAMRA CONSTANTINE G 2010-01-28 US disclosed
US-7645747-B2 Improved pharmacokinetic properties, oral bioavailability; side effect reduction GILEAD SCIENCES, INC. (US) 2010-01-12 US disclosed
US-20090181930-A1 KINASE INHIBITORY PHOSPHONATE ANALOGS CANNIZZARO CARINA 2009-07-16 US disclosed
US-7452901-B2 Anti-cancer phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-11-18 US disclosed
US-7417055-B2 Kinase inhibitory phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-08-26 US disclosed
US-20070281907-A1 Kinase Inhibitor Phosphonate Conjugates GILEAD SCIENCES, INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181930-A1 KINASE INHIBITORY PHOSPHONATE ANALOGS PIK3CA, PNKP, PIK3CB PDGFRB 646/4885CSF1R 1997/4885KIT 1657/4885
US-20100022467-A1 ANTI-CANCER PHOSPHONATE ANALOGS PIK3CA, PHOSPHO1, PTEN PDGFRB 644/4885CSF1R 2390/4885KIT 3880/4885
US-20070281907-A1 Kinase Inhibitor Phosphonate Conjugates PIK3CA, PNKP, PLK1 PDGFRB 618/4885CSF1R 1071/4885KIT 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.